Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

10.1038/leu.2016.186

Saved in:

Bibliographic Details
Main Authors:	Moreau, P, Joshua, D, Chng, W-J, Palumbo, A, Goldschmidt, H, Hajek, R, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosinol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, HH, Mohamed, N, Aggarwal, S, Feng, S, Dimopoulos, MA
Other Authors:	DEAN'S OFFICE (MEDICINE)
Format:	Article
Language:	English
Published:	NATURE PUBLISHING GROUP 2022
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology Hematology STEM-CELL TRANSPLANTATION LENALIDOMIDE MAINTENANCE RETREATMENT INHIBITOR
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/229017
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

id	sg-nus-scholar.10635-229017
record_format	dspace
spelling	sg-nus-scholar.10635-2290172023-10-31T20:52:57Z Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study Moreau, P Joshua, D Chng, W-J Palumbo, A Goldschmidt, H Hajek, R Facon, T Ludwig, H Pour, L Niesvizky, R Oriol, A Rosinol, L Suvorov, A Gaidano, G Pika, T Weisel, K Goranova-Marinova, V Gillenwater, HH Mohamed, N Aggarwal, S Feng, S Dimopoulos, MA DEAN'S OFFICE (MEDICINE) Science & Technology Life Sciences & Biomedicine Oncology Hematology STEM-CELL TRANSPLANTATION LENALIDOMIDE MAINTENANCE RETREATMENT INHIBITOR 10.1038/leu.2016.186 LEUKEMIA 31 1 115-122 2022-07-21T07:28:52Z 2022-07-21T07:28:52Z 2017-01-01 2022-07-17T12:14:28Z Article Moreau, P, Joshua, D, Chng, W-J, Palumbo, A, Goldschmidt, H, Hajek, R, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosinol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, HH, Mohamed, N, Aggarwal, S, Feng, S, Dimopoulos, MA (2017-01-01). Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. LEUKEMIA 31 (1) : 115-122. ScholarBank@NUS Repository. https://doi.org/10.1038/leu.2016.186 08876924 14765551 https://scholarbank.nus.edu.sg/handle/10635/229017 en NATURE PUBLISHING GROUP Elements
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
language	English
topic	Science & Technology Life Sciences & Biomedicine Oncology Hematology STEM-CELL TRANSPLANTATION LENALIDOMIDE MAINTENANCE RETREATMENT INHIBITOR
spellingShingle	Science & Technology Life Sciences & Biomedicine Oncology Hematology STEM-CELL TRANSPLANTATION LENALIDOMIDE MAINTENANCE RETREATMENT INHIBITOR Moreau, P Joshua, D Chng, W-J Palumbo, A Goldschmidt, H Hajek, R Facon, T Ludwig, H Pour, L Niesvizky, R Oriol, A Rosinol, L Suvorov, A Gaidano, G Pika, T Weisel, K Goranova-Marinova, V Gillenwater, HH Mohamed, N Aggarwal, S Feng, S Dimopoulos, MA Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
description	10.1038/leu.2016.186
author2	DEAN'S OFFICE (MEDICINE)
author_facet	DEAN'S OFFICE (MEDICINE) Moreau, P Joshua, D Chng, W-J Palumbo, A Goldschmidt, H Hajek, R Facon, T Ludwig, H Pour, L Niesvizky, R Oriol, A Rosinol, L Suvorov, A Gaidano, G Pika, T Weisel, K Goranova-Marinova, V Gillenwater, HH Mohamed, N Aggarwal, S Feng, S Dimopoulos, MA
format	Article
author	Moreau, P Joshua, D Chng, W-J Palumbo, A Goldschmidt, H Hajek, R Facon, T Ludwig, H Pour, L Niesvizky, R Oriol, A Rosinol, L Suvorov, A Gaidano, G Pika, T Weisel, K Goranova-Marinova, V Gillenwater, HH Mohamed, N Aggarwal, S Feng, S Dimopoulos, MA
author_sort	Moreau, P
title	Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
title_short	Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
title_full	Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
title_fullStr	Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
title_full_unstemmed	Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
title_sort	impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 endeavor study
publisher	NATURE PUBLISHING GROUP
publishDate	2022
url	https://scholarbank.nus.edu.sg/handle/10635/229017
_version_	1781793152302055424

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

Similar Items